Applied Therapeutics (APLT) Revenue & Revenue Breakdown
Applied Therapeutics Revenue Highlights
Latest Revenue (Y)
$9.99M
Latest Revenue (Q)
$190.00K
Main Segment (Y)
License
Applied Therapeutics Revenue by Period
Applied Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $9.99M | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
Applied Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $190.00K | -128.49% |
2023-12-31 | $-667.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | -100.00% |
2023-03-31 | $10.66M | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
Applied Therapeutics Revenue Breakdown
Applied Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 |
---|---|
License | $9.22M |
Research and Development Services | $774.00K |
Quarterly Revenue by Product
Product/Service | Mar 24 |
---|---|
Research and Development Services | $190.00K |
Applied Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOOK | HOOKIPA Pharma | $20.13M | - |
SEER | Seer | $16.66M | $3.07M |
APLT | Applied Therapeutics | $9.99M | $190.00K |
MOLN | Molecular Partners | $7.04M | $2.74M |
STTK | Shattuck Labs | $1.66M | $1.61M |
LYRA | Lyra Therapeutics | $1.56M | $598.00K |
TFFP | TFF Pharmaceuticals | $733.87K | $650.22K |
LIFE | aTyr Pharma | $353.00K | $235.00K |
GANX | Gain Therapeutics | $55.18K | - |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
XFOR | X4 Pharmaceuticals | - | $563.00K |
BCAB | BioAtla | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INAB | IN8bio | - | - |
TERN | Terns Pharmaceuticals | - | - |
ACRV | Acrivon Therapeutics | - | - |
PMVP | PMV Pharmaceuticals | - | - |
MLYS | Mineralys Therapeutics | - | - |
VINC | Vincerx Pharma | - | - |
ORIC | ORIC Pharmaceuticals | - | - |
LTRN | Lantern Pharma | - | - |
APLT Revenue FAQ
What is Applied Therapeutics’s yearly revenue?
Applied Therapeutics's yearly revenue for 2023 was $9.99M, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. APLT's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Applied Therapeutics’s quarterly revenue?
Applied Therapeutics's quarterly revenue for Q1 2024 was $190K, a -128.49% decrease from the previous quarter (Q4 2023), and a -98.22% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $-667K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). APLT's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Applied Therapeutics’s revenue growth rate?
Applied Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.
What are Applied Therapeutics’s revenue streams?
Applied Therapeutics's revenue streams in c 23 are License, and Research and Development Services. License generated $9.22M in revenue, accounting 92.25% of the company's total revenue Research and Development Services generated $774K in revenue, accounting 7.75% of the company's total revenue
What is Applied Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Applied Therapeutics was License. This segment made a revenue of $9.22M, representing 92.25% of the company's total revenue.